These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29443301)

  • 1. An overview of third-generation antiseizure drugs: Clobazam, lacosamide, rufinamide, and vigabatrin.
    Spanaki MV; Barkley GL
    Neurol Clin Pract; 2012 Sep; 2(3):236-241. PubMed ID: 29443301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiepileptic drugs: lacosamide, rufinamide, and vigabatrin.
    Strom LA; Koh S; Frey L
    Curr Treat Options Neurol; 2010 Jul; 12(4):287-99. PubMed ID: 20842588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.
    Cramer JA; Sapin C; François C
    Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
    Gresham J; Eiland LS; Chung AM
    Neuropsychiatr Dis Treat; 2010 Oct; 6():639-45. PubMed ID: 20957124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on rufinamide in childhood epilepsy.
    Coppola G
    Neuropsychiatr Dis Treat; 2011; 7():399-407. PubMed ID: 21792306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
    Sills GJ
    Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
    Striano P; McMurray R; Santamarina E; Falip M
    Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
    Wisniewski CS
    Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
    Besag FMC; Vasey MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review.
    Balagura G; Riva A; Marchese F; Verrotti A; Striano P
    Neuropsychiatr Dis Treat; 2020; 16():369-379. PubMed ID: 32103957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
    Nikanorova M; Brandt C; Auvin S; McMurray R
    Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.
    Leahy JT; Chu-Shore CJ; Fisher JL
    Neuropsychiatr Dis Treat; 2011; 7():673-81. PubMed ID: 22128252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.
    Lee EH; Yum MS; Ko TS
    Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome.
    Clements KM; Skornicki M; O'Sullivan AK
    Epilepsy Behav; 2013 Oct; 29(1):184-9. PubMed ID: 23973644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Can an Na
    Lin YC; Lai YC; Chou P; Hsueh SW; Lin TH; Huang CS; Wang RW; Yang YC; Kuo CC
    Ann Neurol; 2021 Jun; 89(6):1099-1113. PubMed ID: 33745195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
    Kanner AM; Ashman E; Gloss D; Harden C; Bourgeois B; Bautista JF; Abou-Khalil B; Burakgazi-Dalkilic E; Llanas Park E; Stern J; Hirtz D; Nespeca M; Gidal B; Faught E; French J
    Neurology; 2018 Jul; 91(2):82-90. PubMed ID: 29898974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.
    Faulkner MA
    Ther Clin Risk Manag; 2015; 11():905-14. PubMed ID: 26089675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
    Kim SH; Kang HC; Lee JS; Kim HD
    Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Leppien EE; Doughty BJ; Hurd KL; Strong KN; Piper BJ; McCall KL
    Clin Drug Investig; 2023 Jun; 43(6):393-399. PubMed ID: 37184612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
    Coppola G; Besag F; Cusmai R; Dulac O; Kluger G; Moavero R; Nabbout R; Nikanorova M; Pisani F; Verrotti A; von Stülpnagel C; Curatolo P
    Eur J Paediatr Neurol; 2014 Nov; 18(6):685-90. PubMed ID: 24929673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.